These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23868464)

  • 21. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R
    Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S; Zhang W; Huang L; Jiang H
    PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.
    Santra S; Bhattacharya A; Mukhopadhyay T; Agrawal D; Kumar S; Das P; Chakrabarty P
    Mymensingh Med J; 2015 Oct; 24(4):838-44. PubMed ID: 26620028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
    Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
    Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferiprone chelation therapy for thalassemia major.
    Galanello R; Campus S
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature review.
    Zhang B; Donga PZ; Corral M; Sasane M; Miller JD; Pashos CL
    Pharmacoeconomics; 2011 Jun; 29(6):461-74. PubMed ID: 21452907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.
    Sari TT; Wahidiyat PA; Rahmartani LD; Iskandar SD; Putri IA
    J Pediatr Hematol Oncol; 2024 Aug; 46(6):e402-e405. PubMed ID: 38832436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
    Tripathy I; Panja A; Dolai TK; Mallick AK
    Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.